Opus Genetics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IRD | OCGN | MGTX | RGNX | SIGHT.PA | STOK | |
|---|---|---|---|---|---|---|
| Market cap | 355.25M | 296.55M | 904.72M | 508.96M | 16.92M | 1.78B |
| P/E (TTM) | — | — | 10.8 | — | — | — |
| Forward P/E | -6.0 | -3.5 | -6.2 | -2.6 | -0.1 | -7.3 |
| Price/book | -27.2 | -16.8 | 4.1 | 5.8 | -0.5 | 5.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +85.38% | −47.16% | +10.96% | −34.28% | −45.76% | +18.27% |
| Today | +8.65% | +17.35% | −1.05% | +1.05% | −0.29% | +1.70% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IRD news ›Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
The Manila Times RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) ("Opus Genetics” or the "Company”), a clinical-stage biopharmaceutical company developing gene therapi
More from 1 other outlet
Opus Genetics (IRD) Set to Post Quarterly Earnings on Wednesday
Posted by Sarita Garza on Nov 4th, 2026 Shares of Opus Genetics stock opened at $3.93 on Wednesday. Opus Genetics has a 52 week low of $1.70 and a 52 week high of $7.07. The business’s fifty day simple moving average is $4.46 and its…
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
The Manila Times The equity awards were granted in the form of options to purchase an aggregate of 1,100,000 shares of the Company’s common stock. The option awards have an exercise price equal to the fair market value of a
Opus Genetics Makes Leadership Moves to Advance Gene Plan
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), has announced…
Head to Head Contrast: Opus Genetics (NASDAQ:IRD) versus Alkermes (NASDAQ:ALKS)
Posted by Mitch Edgeman on Oct 31st, 2026 Opus Genetics (NASDAQ:IRD – Get Free Report) and Alkermes (NASDAQ:ALKS – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based…
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical... Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart…
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses link retinal…
Nucelion Therapeutics, Pandorum Technologies to take up 2 ophthalmology projects
Nucelion Therapeutics, a gene therapy CDMO and an arm of Bharat Biotech, and Pandorum Technologies, a tissue engineering and regenerative medicine company, will take up two ophthalmology projects focused on developing investigational…
More from 1 other outlet
Comparing Opus Genetics (NASDAQ:IRD) & Cardiff Oncology (NASDAQ:CRDF)
Posted by Danessa Lincoln on Oct 27th, 2026 Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the…
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
Posted by Defense World Staff on Oct 27th, 2026 Opus Genetics (NASDAQ:IRD) outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com10
- stocktitan.net4
- themarketsdaily.com4
- defenseworld.net2
- manilatimes.net2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 31 articles, not a forecast.